SUBSCRIBE

Breaking News on Contract Research, Manufacturing & Clinical Trials

Headlines > Clinical Development

Read more breaking news

 

 

inVentiv preps for $100m IPO

By Gareth MacDonald+

06-Apr-2016
Last updated on 06-Apr-2016 at 17:03 GMT2016-04-06T17:03:15Z

inVentiv preps for $100m IPO

US CRO inVentiv Health has signaled its intention to go public by filing an S1 with the Securities and Exchange Commission (SEC) last night.

According to the S1 , which was filed by parent company inVentiv Group Holding, the Burlington, Massachusetts-based contract services organisation hopes to raise $100m by listing on either the New York Stock Exchange or the NASDAQ Global Market.

inVentiv has been owned by US private equity group Thomas H Lee Partners (THL), which acquired the contractor in 2010 for $1.1bn (€845m).

According to the S1, inVentiv generated net revenues of $1.99bn last year, which is an increase of 10.4% year-on-year.

The document also reveals that the firm's clinical trial business generated revenue of $947m, up 8.9%, while its commercial services unit – which helps drug firms launch products – saw sales of $1bn, which is up 12.3% from 2014.

inVentiv claims to have a client base of more than 550 organizations, including the 20 of the largest global biopharmaceutical companies.

It also says that over 80% of all new molecular entities approved by the US FDA and 70% of those approved by the EMA over the last five years "have been developed or commercialized with our support."

Related products

Related suppliers

Key Industry Events